EU Panel Recommends Hydroxycarbamide for Sickle Cell Disease EU Panel Recommends Hydroxycarbamide for Sickle Cell Disease

An EMA committee recommended marketing authorization for hydroxycarbamide for the prevention of vaso-occlusive complications of sickle cell disease in patients older than 2 years.International Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news